Diabetes mellitus

• Název v anglickém jazyce: Diabetes mellitus
• Akademický rok vypsání: 2011/2012
• Typ práce: diplomová práce
• Jazyk práce: angličtina
• Ústav: Katedra biologických a lékařských věd (16-16150)
• Vedoucí / školitel: prof. PharmDr. Petr Nachtigal, Ph.D.
• Řešitel: skrytý - zadáno vedoucím/školitelem
• Datum přihlášení: 28.11.2011
• Datum zadání: 02.11.2012
• Datum a čas obhajoby: 07.06.2013 00:00
• Datum odevzdání elektronické podoby: 06.05.2013
• Datum proběhlé obhajoby: 07.06.2013
• Oponenti: doc. MUDr. Josef Herink, DrSc.

Zásady pro vypracování

Literature review.

Seznam odborné literatury

1 M. Zhang, X. Y. Lv, J. Li, Z. G. Xu and L. Chen, 'The characterization of high-fat diet and multiple low-dose streptozotocin induced type 2 diabetes rat model', Exp Diabetes Res, 2008 (2008), p. 704045.
2 W. Malakul, S. Thirawarapan, W. Suvitayavat and O. L. Woodman, 'Type 1 diabetes and hypercholesterolaemia reveal the contribution of endothelium-derived hyperpolarizing factor to endothelium-dependent relaxation of the rat aorta', Clin Exp Pharmacol Physiol, 35 (2008), pp. 192-200.
3 V. Kristova, S. Liskova, R. Sotnikova, R. Vojtko and A. Kurtansky, 'Sulodexide improves endothelial dysfunction in streptozotocin-induced diabetes in rats', Physiol Res, 57 (2008), pp. 491-4.
4 V. C. Sandrim, R. W. de Syllos, H. R. Lisboa, G. S. Tres and J. E. Tanus-Santos, 'Influence of eNOS haplotypes on the plasma nitric oxide products concentrations in hypertensive and type 2 diabetes mellitus patients', Nitric Oxide, 16 (2007), pp. 348-55.
5 O. Rubio Cabezas and J. Argente Oliver, '[Diabetes mellitus in children and adolescents: chronic complications and associated diseases]', An Pediatr (Barc), 66 (2007), pp. 282-9.
6 P. H. Jones, 'Clinical significance of recent lipid trials on reducing risk in patients with type 2 diabetes mellitus', Am J Cardiol, 99 (2007), pp. 133B-40B.
7 J. Singh, A. Chonkar, N. Bracken, E. Adeghate, Z. Latt and M. Hussain, 'Effect of streptozotocin-induced type 1 diabetes mellitus on contraction, calcium transient, and cation contents in the isolated rat heart', Ann N Y Acad Sci, 1084 (2006), pp. 178-90.
8 F. Persson, P. Rossing, P. Hovind, C. D. Stehouwer, C. Schalkwijk, L. Tarnow and H. H. Parving, 'Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudy', Diabetes, 55 (2006), pp. 3550-5.
9 A. Nitenberg, '[Endothelial dysfunction in patients with diabetes: identification, pathogenesis and treatment]', Presse Med, 34 (2005), pp. 1654-61.
10 R. S. Scheffel, D. Bortolanza, C. S. Weber, L. A. Costa, L. H. Canani, K. G. Santos, D. Crispim, I. Roisenberg, H. R. Lisboa, G. S. Tres, B. Tschiedel and J. L. Gross, '[Prevalence of micro and macroangiopatic chronic complications and their risk factors in the care of out patients with type 2 diabetes mellitus]', Rev Assoc Med Bras, 50 (2004), pp. 263-7.
11 J. F. Morrison, S. Dhanasekaran and R. Sheen, 'Effects of age and streptozotocin-induced diabetes on biogenic amines in rat tail artery', Mol Cell Biochem, 261 (2004), pp. 77-82.
12 R. B. D'Agostino, Jr., R. F. Hamman, A. J. Karter, L. Mykkanen, L. E. Wagenknecht and S. M. Haffner, 'Cardiovascular disease risk factors predict the development of type 2 diabetes: the insulin resistance atherosclerosis study', Diabetes Care, 27 (2004), pp. 2234-40.
13 D. Bonnefont-Rousselot, J. L. Beaudeux, P. Therond, J. Peynet, A. Legrand and J. Delattre, '[Diabetes mellitus, oxidative stress and advanced glycation endproducts]', Ann Pharm Fr, 62 (2004), pp. 147-57.
14 S. F. Yan, R. Ramasamy, Y. Naka and A. M. Schmidt, 'Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond', Circ Res, 93 (2003), pp. 1159-69.
15 N. N. Chan, P. Vallance and H. M. Colhoun, 'Endothelium-dependent and -independent vascular dysfunction in type 1 diabetes: role of conventional risk factors, sex, and glycemic control', Arterioscler Thromb Vasc Biol, 23 (2003), pp. 1048-54.
16 K. F. Petersen and G. I. Shulman, 'Pathogenesis of skeletal muscle insulin resistance in type 2 diabetes mellitus', Am J Cardiol, 90 (2002), pp. 11G-8G.
17 J. D. McGarry, 'Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes', Diabetes, 51 (2002), pp. 7-18.
18 K. Kalogeropoulou, G. Mortzos, I. Migdalis, C. Velentzas, D. P. Mikhailidis, E. Georgiadis and P. Cordopatis, 'Carotid atherosclerosis in type 2 diabetes mellitus: potential role of endothelin-1, lipoperoxides, and prostacyclin', Angiology, 53 (2002), pp. 279-85.
19 Y. Hata and T. Ishibashi, '[Chronic complications due to diabetes mellitus: Pathology of diabetic retinopathy]', Nippon Rinsho, 60 Suppl 10 (2002), pp. 155-61.
20 B. K. Bailes, 'Diabetes mellitus and its chronic complications', AORN J, 76 (2002), pp. 266-76, 78-82; quiz 83-6.

Předběžná náplň práce v anglickém jazyce

Literature review.